CBD_SBIR_254_R4.pdf

PDF 347 KB Posted

Attached to
Prophylactics/Therapeutics for Neurotoxin Exposure
Solicitation number
CBD254-004
Issued by

About this file

This document is the Proposal Submission Instructions and Topic Index for the Chemical and Biological Defense (CBD) Small Business Innovation Research (SBIR) Program FY25.4 Release 4, managed by the Joint Science and Technology Office for Chemical and Biological Defense (JSTO CBD) at the Defense Threat Reduction Agency (DTRA).

The solicitation invites Phase I and Direct to Phase II proposals across four research topics focused on improving chemical and biological defense capabilities: alternatives to eliminate cold chain requirements for medical countermeasures (CBD254-001); production of sterile saline and water for injection deployable forward (CBD254-002); regenerable CO2 scrubbing in self-contained breathing apparatus (CBD254-003); and prophylactics/therapeutics for neurotoxin exposure (CBD254-004). Phase I proposals are limited to 20 pages with a maximum award of $209,575 for up to six months of performance. Direct to Phase II proposals are limited to 15 pages (5 pages feasibility documentation plus 10 pages technical proposal) with maximum awards of $698,582.50 for 12 months base plus a 12-month option not to exceed $1,397,165.00 total. All proposals must be submitted through the Defense SBIR/STTR Innovation Portal (DSIP) at https://www.dodsbirsttr.mil. Phase I awardees are eligible to compete in Phase II; Phase II submission cannot occur before five months after Phase I contract award. Proposals are evaluated on three criteria per the DoD Program BAA. The CBD SBIR program reserves the right to limit awards, withdraw from negotiations for national security reasons, and may elect to fund multiple or no approaches to the same topic. Offerors must disclose foreign nationals, green card holders, and dual citizens involved on projects, and comply with all DoD SBIR requirements including human subjects, animal use, and intellectual property ownership verification for Direct to Phase II applicants.

View the file

Other files

File Type Posted
CBD254-004.pdf PDF

On GovTribe

Work with this file

  • Download the original file
  • Contacts named in this file
  • Similar government files
  • Ask GovTribe AI about this file

Text version

Cleared for Public Release

CBD – 1

CHEMICAL AND BIOLOGICAL DEFENSE PROGRAM

FY25.4 Small Business Innovation Research (SBIR)

Release 4 Proposal Submission Instructions

The approved FY25.4 topics included in the Chemical and Biological Defense (CBD) Small Business Innovation Research (SBIR) Program is provided in this document. Offerors responding to this Announcement must follow all general instructions provided in the Department of Defense (DoD) Program Announcement, as well as the CBD SBIR Topic Instructions provided below, detailing specific CBD SBIR program requirements.

Proposers are encouraged to thoroughly review the DoD Program Broad Agency Announcement (BAA), as well as register for the DoD SBIR/STTR Innovation Portal (DSIP) Listserv to remain apprised of important programmatic and contractual changes.

• The DoD Program BAA: https://www.dodsbirsttr.mil/submissions/solicitation-documents/active-solicitations. Be sure to select the tab for the appropriate BAA cycle.

• Register for the DSIP Listserv at: https://www.dodsbirsttr.mil/

Please read the entire DoD Announcement and these CBD SBIR instructions carefully prior to submitting your proposal. Important programmatic changes have been incorporated as required by the SBIR and STTR Extension Act of 2022 (Pub. L. 117-183). Also, go to https://www.sbir.gov/about/policies to read the SBIR/STTR Policy Directive issued by the U. S. Small Business Administration (SBA).

INTRODUCTION

In response to Congressional interest in the readiness and effectiveness of U.S. Nuclear, Biological and Chemical (NBC) warfare defenses, Title XVII of the National Defense Authorization Act for Fiscal Year 1994 (Public Law 103-160) requires the Department of Defense (DoD) to consolidate management and oversight of the Chemical and Biological Defense Program (CBDP) into a single office – Office of the Assistant Secretary of Defense for Nuclear, Chemical and Biological Defense Programs. The Joint Science and Technology Office for Chemical and Biological Defense (JSTO CBD), located at the Defense Threat Reduction Agency (DTRA), provides the management for the Science and Technology component of the Chemical and Biological Defense Program. Technologies developed under the Small Business Innovation Research (SBIR) Program have the potential to transition to the Joint Program Executive Office for Chemical Biological Radiological and Nuclear Defense (JPEO CBRND) if the appropriate level of technology maturity is demonstrated. The JSTO CBD Science & Technology programs and initiatives improve defensive capabilities against Chemical and Biological Weapons of Mass Destruction. The SBIR portion of the CBD Program is managed by

JSTO CBD.

The mission of the Chemical and Biological Defense Program is to ensure that the U.S. Military has the capability to operate effectively and decisively in the face of chemical or biological warfare threats at home or abroad. Numerous factors continually influence the program and its technology development priorities. Improved defensive capabilities are essential to mitigate the overall impact of chemical and biological threats. The U.S. military requires the finest state-of-the-art equipment and instrumentation available to permit our Joint Force to ‘detect to warn’ and avoid contamination, if possible – and to be able to sustain operations in a potentially contaminated environment. Further information is available at the Office of the Assistant Secretary of Defense for Nuclear, Chemical, and Biological Defense Programs homepage at https://www.acq.osd.mil/ncbdp/cbd/ https://www.dodsbirsttr.mil/submissions/solicitation-documents/active-solicitations https://www.dodsbirsttr.mil/submissions/solicitation-documents/active-solicitations http://www.dodsbirsttr.mil/ https://www.sbir.gov/about/policies https://www.acq.osd.mil/ncbdp/cbd/

CBD – 2

The overall objective of the CBD SBIR Program is to improve the transition or transfer of innovative Chem-Bio technologies to the end user – the Joint Force – in addition to commercializing technologies within the private sector for mutual benefit. The CBD SBIR Program targets those technology efforts that maximize a strong defensive posture in a biological or chemical environment using passive and active means as deterrents. These technologies include chemical and biological detection for both point and stand-off capabilities; individual and collective protection; hazard mitigation (decontamination); medical pre-treatments (e.g., vaccine development and delivery); medical therapeutics (chemical and biological countermeasures); medical diagnostics; information systems technology to include but not limited to modeling and simulation (e.g., meteorological dispersion), disease surveillance, data fusion, and health & human effects to include wearable technologies.

All proposals submitted to the CBD SBIR program must comply to the terms of this Announcement.

CBD SBIR reserves the right to limit awards under any topic, and only those proposals of superior scientific and technical quality, as determined by Technical Evaluation Team and the CBD SBIR program office will be funded. CBD SBIR reserves the right to withdraw from negotiations at any time prior to contract award. The Government may withdraw from negotiations at any time for any reason to include matters of national security (foreign persons, foreign influence or ownership, or other related issues).

Use of Foreign Nationals (also known as Foreign Persons), Green Card Holders, and Dual Citizens

See the “Foreign Nationals” section of the DoD SBIR Program Announcement for the definition of a Foreign National (also known as Foreign Persons).

It is the responsibility of ALL offerors proposing who use foreign nationals, green-card holders, or dual citizens, to disclose this information regardless of whether the topic is subject to export control restrictions. Offerors MUST identify any foreign nationals or individuals holding dual citizenship expected to be involved on this project as a direct employee, subcontractor, or consultant. For these individuals, specify their country of origin, the type of visa or work permit under which they are performing and an explanation of their anticipated level of involvement on the project. You may be asked to provide additional information during contract negotiations to verify the foreign citizen’s eligibility to participate on a SBIR contract. Supplemental information provided in response to this paragraph will be protected in accordance with the Privacy Act (5 U.S.C. 552a), if applicable, and the Freedom of Information Act (5 U.S.C. 552(b)(6)).

Proposers responding to this BAA must follow all general instructions provided in the Department of Defense (DoD) SBIR Program BAA, paying special attention to the new requirements under the SBIR and STTR Extension Act of 2022 (Pub. L. 117-183). The Chemical and Biological Defense SBIR Program requirements are provided in the instructions below.

Specific questions pertaining to the administration of the Chemical and Biological Defense SBIR Program and these proposal preparation instructions should be directed to: Ms. Abigail L. Roots, Chemical and Biological Defense SBIR/STTR Program Manager, JSTO CBD, at dtra.belvoir.rd.mbx.jsto- cbd-chem-bio-defense-sbir@mail.mil.

CBD SBIR instructions are for research topics accepting Phase I or Direct to Phase II proposals.

Separate guidance will be issued requesting Phase II proposals, and unsolicited proposals will not be accepted. All proposing SBCs that receive a Phase I award from this BAA will be eligible to participate mailto:dtra.belvoir.rd.mbx.jsto-cbd-chem-bio-defense-sbir@mail.mil

CBD – 3

in Phase II competitions. CBD SBIR program office will notify Phase I awardees of the Phase II proposal submission requirements.

CBD SBIR program office is not obligated to make any awards under Phase I and Phase II and is not responsible for any monies the proposing small business concern (SBC) spends before any award issuance. Proposals must conform to this announcement’s terms. CBD SBIR program office is under no obligation to fund any proposal or any specific number of proposals in each topic. It also may elect to fund several or none of the proposed approaches to the same topic.

PHASE I PROPOSAL GUIDELINES

The Defense SBIR/STTR Innovation Portal (DSIP) is the official portal for DoD SBIR/STTR proposal submission. Firms are required to submit proposals via DSIP; proposals submitted by any other means will be disregarded. Detailed instructions regarding registration and proposal submission are provided in the DoD SBIR Program BAA.

a. Proposal Coversheet (Volume 1) The proposal coversheet must follow the instructions and requirements provided in the DoD SBIR Program BAA.

The offeror shall certify that to the best of its knowledge and belief, its eligibility information under the SBIR Program is accurate, complete, and current as of the date of the offer.

b. Technical Volume (Volume 2) The technical volume is not to exceed 20-pages and must follow the formatting requirements provided in the DoD SBIR Program BAA. No other information included in the other proposal volumes will count against the Proposal Technical Volume page limit. Pages provided exceeding this length will not be considered for review. The proposal must not contain any font type smaller than 10-point font size (except as a legend on reduced drawings, but not in the tables).

The maximum dollar amount for a Phase I proof-of-concept/feasibility study is $209,575.00 for a period of performance (PoP) of up to six (6) months. The CBD SBIR Program will not accept proposals exceeding this amount for the Phase I effort.

The entire proposal submission must be through the Defense SBIR/STTR Innovation Portal (DSIP) located at: https://www.dodsbirsttr.mil. Any questions pertaining to the DoD SBIR/STTR submission process and system should be directed to DSIP Support:

DoDSBIRSupport@reisystems.com

Selection of Phase I proposals will be based upon the three (3) evaluation criteria as mentioned in the DoD BAA. The CBD SBIR Program reserves the right to limit awards under any topic, and only those proposals of superior scientific and technical quality deemed by the Technical Evaluation Team will be funded. All SBIR contract awards, both Phase I and Phase II, are subject to availability of funding.

The brief Period of Performance available for a Phase I project precludes plans that include research involving human or animal subjects as all associated DoD requirements and the necessary approvals must be strictly adhered to and require considerable coordination and significant time for final protocol approvals. See “Research Involving Human Subjects, Biospecimens, and/or Animal Use,” below for further information.

https://www.dodsbirsttr.mil/ mailto:DoDSBIRSupport@reisystems.com

CBD – 4

Proposals not conforming to the terms of this Announcement, and any unsolicited proposals, will not be considered. All awards are subject to the availability of funding and successful completion of contract negotiations. The Chemical and Biological Defense Program is not responsible for any funds expended by the proposer prior to contract award.

c. Cost Volume (Volume 3) The Cost Volume must follow all instructions and requirements provided in the DoD SBIR Program BAA. The Phase I Base amount must not exceed $209,575.00. Total Base cost for Phase I must be clearly identified on the Proposal Cover Sheet (Volume 1) and in Volume 3.

d. Company Commercialization Report (CCR) (Volume 4) Completion of the CCR is required and included in Volume 4 of the DSIP portal. Please refer to the DoD SBIR Program BAA for full details on this requirement. Information contained in the CCR will not be considered by the Chemical and Biological Defense Program in the proposal evaluations.

e. Supporting Documents (Volume 5)

Volume 5 is provided for proposing SBCs to submit additional documentation to support the Coversheet (Volume 1), Technical Volume (Volume 2), and the Cost Volume (Volume 3). Please refer to the DoD Program BAA for more information. Offerors are welcome to provide Supporting Documents in this section, however these documents will not be considered by the Chemical and Biological Defense Program in the proposal evaluations.

f. Fraud, Waste and Abuse (Volume 6) All offerors must complete the Fraud, Waste, and Abuse training through the DSIP portal (https://www.dodsbirsttr.mil). Please follow the guidance provided via DSIP to complete the required training prior to proposal submission.

To Report Fraud, Waste, or Abuse, please contact:

DoD Inspector General (IG) Fraud, Waste & Abuse Hotline: (800) 424-9098 hotline@dodig.mil

Additional information on Fraud, Waste and Abuse may be found in the DoD Announcement.

g. Disclosures of Foreign Affiliations or Relationships to Foreign Countries (Volume 7)

Small business concerns must complete the Disclosures of Foreign Affiliations or Relationships to Foreign Countries webform in Volume 7 of the DSIP proposal submission. Please be aware that the Disclosures of Foreign Affiliations or Relationships to Foreign Countries WILL NOT be accepted as a PDF Supporting Document in Volume 5 of the DSIP proposal submission. Do not upload any previous versions of this form to Volume 5. For additional details, please refer to the DoD Program BAA.

DIRECT TO PHASE II PROPOSAL GUIDELINES

The Chemical and Biological Defense SBIR Program is participating in Direct to Phase II, only as detailed in the topic documentation. Not all topics include Direct to Phase II option.

Implementing the authority granted by 15 U.S.C. §638 (cc), as amended by the SBIR AND STTR EXTENSION ACT OF 2022, the CBD will be conducting ‘Direct to Phase II’ contract awards for eligible SBIR topics. Each eligible topic requires documentation to determine whether the feasibility requirement described in the Phase I section of the topic has been met.

mailto:hotline@dodig.mil

CBD – 5

Each eligible topic requires proposing SBCs provide documentation to demonstrate feasibility described in the Phase I section of the topic has been met. Feasibility documentation cannot be based upon or logically extend from any prior or ongoing federally funded SBIR or STTR work. The proposing SBC and/or the principal investigator must have substantially performed the work submitted in the feasibility documentation. If technology in the feasibility documentation is subject to intellectual property (IP), the proposing SBC must demonstrate ownership or licensure of the IP associated with such technology prior to proposal submission to enable it and its subcontractors to legally carry out the proposed work.

If the proposing SBC fails to demonstrate technical merit and feasibility equivalent to the Phase I level as described in the associated topic, the related Phase II proposal will not be accepted or evaluated, in accordance with specific Direct to Phase II instructions.

a. Proposal Cover Sheet (Volume 1) The proposal cover sheet shall follow the instructions and requirements provided in the DoD SBIR 25.4 Program BAA. The offeror shall certify that to the best of its knowledge and belief, its eligibility information under the SBIR Program is accurate, complete, and current as of the date of the offer.

b. Technical Volume Format (Volume 2)

Offerors may submit DP2 proposals only if allowed pursuant to the topic posting. The following technical volume formatting requirements supplement those found within in the DoD SBIR 25.4 Program BAA, including any revisions/amendments.

Guidance for DP2:

Length: For DP2 proposals, the Technical Volume is broken into two (2) sections: Feasibility Documentation, which is subject to a page limitation of five (5) pages; and a Technical Proposal, which is subject to a page limitation of ten (10) pages. The Technical Volume, therefore, shall not exceed fifteen (15) pages and shall follow the formatting requirements provided in the DoD SBIR 25.4 Program BAA. It is the proposing SBC’s responsibility to verify that the Technical Volume does not exceed the page limit after upload to DSIP. Any proposals exceeding the page count limit will be deemed unresponsive.

c. Technical Volume Content (Volume 2)

The following technical volume content instructions supersede those stated in the Phase I Proposal Instruction section above. For DP2 proposals, the technical volume shall include two (2) sections, Feasibility Documentation and a Technical Proposal.

Volume 2A, Feasibility Documentation Feasibility documentation shall not exceed five (5) pages in length.

Proposers interested in submitting a DP2 proposal in response to these topics shall provide documentation to substantiate that the scientific and technical merit and feasibility described in the Phase I section of the topic has been met and describes the potential commercial applications.

Documentation shall include all relevant information including, but not limited to: technical reports (summary and citation), test data, prototype designs/models, and performance goals/results. If references exist, the offeror shall include a reference list or works cited list as the last page of the feasibility documentation. This will count towards the total page limit.

Work submitted within the feasibility documentation must have been substantially performed by the

CBD – 6

proposer and/or the Principal Investigator. Feasibility documentation cannot be based upon any prior or ongoing federally funded SBIR or STTR work and MUST NOT logically extend from any prior or ongoing federally funded SBIR or STTR work. It is the offeror’s responsibility to ensure compliance.

Should the Government find a violation before contract award, the proposal will be rejected. Should the Government find a violation after contract award, the Government has the right to terminate the contract.

If technology in the feasibility documentation is subject to Intellectual Property (IP), the proposing small business concern must either own the IP or must have obtained license rights to such technology prior to proposal submission, to enable it and its subcontractors to legally carry out the proposed work.

If the proposing SBC fails to demonstrate technical merit and feasibility equivalent to the Phase I level as described in the associated topic has been established, or the proposer has failed to demonstrate that work submitted in the feasibility documentation was substantially performed by the proposer and/or the PI the related Phase II proposal will be deemed unresponsive.

Volume 2B, Technical Proposal The technical proposal shall contain two key parts: (1) technical approach and (2) team qualifications.

Volume 2B, Part 1 – Technical Approach. The technical approach section shall explain, in detail, how the offeror is going to solve the specific technical problem or opportunity addressed in the topic. The offeror shall include a statement of work with explicit, detailed descriptions and key elements of the technical approach (including subcontractors’ efforts), any risks, relevant past work and how success was measured along with how success will be measured for this effort. Explain objectives while avoiding technical jargon. The statement of work shall indicate what tasks are planned, how and where the work will be conducted, a schedule of major events and meetings, and the final product(s) to be delivered (reference the ‘Contractual Requirements’ section above). The Phase II effort should attempt to provide proof of concept and prototype development. The methods planned to achieve each objective or task should be discussed explicitly and in detail. This section should be a substantial portion of the Technical Volume section. Note: If the topic allows research or activities involving Human/Animal Subjects and/or Recombinant DNA, offerors shall identify the applicable protocols and how those protocols will be followed.

Volume 2B, Part 2 – Team Qualifications. The team qualifications section shall highlight identify the key personnel working on the project (including information on directly related education and experience), and the resources that will be brought to bear on solving the problem.

Identify any foreign citizens or individuals holding dual citizenship expected to be involved on this project as a direct employee, subcontractor, or consultant. For these individuals, please specify their country of origin, the type of visa or work permit under which they are performing and an explanation of their anticipated level of involvement on this project. Note: You may be asked to provide additional information during proposal evaluation and/or negotiations in order to verify the foreign citizen’s eligibility to participate on a SBIR contract. Supplemental information provided in response to this paragraph will be protected in accordance with the Privacy Act (5 U.S.C. 552a), if applicable, and the Freedom of Information Act (5 U.S.C. 552(b)(6)). The Government may withdraw from negotiations at any time for any reason to include matters of national security (foreign persons, foreign influence or ownership, inability to clear the firm or personnel for security clearances, or other related issues).

CBD – 7

d. Cost Volume (Volume 3) The Direct Phase II base amount must not exceed $698,582.50 with a period of performance (PoP) of twelve (12) months and will include a twelve (12) month option not to exceed the base amount. Total amount of the base and option year is not to exceed $1,397,165.00. Total cost for Direct to Phase II must be clearly identified on the Proposal Cover Sheet. A firm fixed price (FFP) or cost-plus fixed fee Phase II Cost Volume must be submitted in detail. The Cost Volume does not count towards the 50-page Phase II proposal limitation.

PHASE II PROPOSAL GUIDELINES

Offerors may only submit a Phase II proposal after receipt of a Phase I award.

Phase II is the demonstration of the technology that was found feasible in Phase I. A Phase II proposal may not be submitted until sufficient Phase I progress can be evaluated and assessed, and the PoP is nearing completion. The SBC may not submit a Phase II proposal sooner than five (5) months from the date of the Phase I contract award, and upon receiving instructions from the CBD program office.

All Phase II proposal submissions must be submitted on the DSIP portal:

https://www.dodsbirsttr.mil.

At the DSIP website, Phase II proposals MUST be submitted to ‘CBD SBIR’ regardless of which DoD contracting office negotiated and awarded the Phase I contract. Additional instructions regarding the Phase II proposal submission process including submission dates will be provided to Phase I awardees after the Phase I contract is awarded.

The Phase II proposal must include a concise summary of the Phase I project including the specific technical problem or opportunity addressed in the proposal. The proposal must also include an objective statement, the type of research conducted, findings and/or results of the research, and technical feasibility of the technology. Due to limited funding, the CBD SBIR program reserves the right to limit awards under any topic and only proposals considered to be of superior quality will be funded.

All proposers are required to submit a commercialization plan that describes the SBC’s marketing and manufacturing approach to developing the technology. The Offeror is required to submit a budget for the entire 24-month Phase II Period of Performance. During contract negotiation, the Contracting Officer may require a Cost Volume for a base year and an option year; thus, proposers are advised to be aware of this possibility. These costs must be submitted using the Cost Volume format within the DSIP website. The total proposed amount should be indicated on the Proposal Cover Sheet as the Proposed Cost. At the Contracting Officer’s discretion, Phase II projects may be evaluated for technical progress prior to the end of the base year (year one), to decide whether to extend the funding for the option year (year two).

The CBD SBIR Program is committed to minimizing the funding gap between Phase I and Phase II activities. The CBD SBIR Program typically funds a cost-plus fixed fee Phase II award at the discretion of the Contracting Officer but may award a firm fixed price contract.

It is recommended that Phase II awardees have a Defense Contract Audit Agency (DCAA) approved accounting system. If you do not have a DCAA approved accounting system, this could delay/prevent a Phase II contract award. Visit https://www.dcaa.mil/Customers/Small-Business for more information on DCAA approved accounting systems.

https://www.dcaa.mil/Customers/Small-Business

CBD – 8

DISCRETIONARY TECHNICAL AND BUSINESS ASSISTANCE (TABA)

Currently, the CBD SBIR Program does not participate in the Technical and Business Assistance (TABA) Program.

EVALUATION AND SELECTION

All proposals will be evaluated in accordance with the evaluation criteria listed in the DoD SBIR Program BAA.

Offerors will be notified of selection or non-selection within the 90-day window requirement at the close of the BAA. The CBD SBIR Program office will notify the firm via e-mail to the firm’s Corporate Official (Business Point of Contact) and Principal Investigator, as listed on the Cover Page of the proposal.

The firm may submit an email request to the CBD SBIR/STTR inbox (https://dtra.belvoir.rd.mbx.jsto-cbd-chem-bio-defense-sbir@mail.mil) to request a technical debrief. The CBD SBIR Program Office will send a debriefing statement within 30-days of the request. The debriefing statement will only be provided to the Corporate Official and the Principal Investigator on the Cover Page of the proposal.

Requests made by the offeror for further information will not be provided.

Refer to the DoD SBIR Program BAA for guidance concerning protests.

As further prescribed in FAR 33.106(b), FAR 52.233-3, Protests after Award should be submitted to Ms. Abigail L. Roots, Chemical and Biological Defense (CBD) SBIR/STTR Program Manager, Joint Science and Technology Office for Chemical and Biological Defense (JSTO CBD), dtra.belvoir.rd.mbx.jsto-cbd- chem-bio-defense-sbir@mail.mil.

RESEARCH INVOLVING HUMAN SUBJECTS, BIOSPECIMENS, AND/OR ANIMAL USE

Any research under a Phase I or Phase II contract involving human subjects, human anatomical substances (e.g., whole blood, cell lines, tissue), and/or animal use must undergo the regulatory review requirements per DoD Instruction 3216.02 and DoD Instruction 3216.01, respectively.

DoD-level review and approval of human and/or animal use are separate from, and in conjunction with the Institutional Review Board (IRB) and/or the Institutional Animal Care and Use Committee

(IACUC).

CBD SBIR Projects Requiring Animal Subjects

Refer to the DoD Program BAA for Research Involving Animal Subjects.

Companies should plan carefully for any research involving animal subjects, in addition to the use of any chemical or biological warfare agents, and use of any agents associated with “Dual Use Research of Concern (DURC)”. The mandatory DoD level review of this research is typically a period of no greater than four (4) months.

Projects under CBD SBIR awards involving the use of animal subjects shall not be proposed for any Phase I Period of Performance but may be proposed during the Phase II proposal submission.

Written authorization to begin animal research under the applicable protocol(s) proposed as part of the CBD SBIR/STTR program will be issued after the contract award in the form of an approval memo from the U.S. Army Medical Research and Development Command (MRDC), Animal Care and Use mailto:cbd-chem-bio-defense-sbir@mail.mil

CBD – 9

Review Office (ACURO), and the Research Oversight Board (ROB) of the Defense Threat Reduction Agency (DTRA), both of which provide DoD compliance oversight to the CBD SBIR and STTR program office.

The offeror is expressly forbidden from using or subcontracting for the use of animals in any manner prior to these approvals. Furthermore, modifications to approved protocols require review and approval by the ACURO prior to implementation.

Non-compliance with these terms and conditions may result in withholding of funds and/or the termination of the award. The ACURO and DTRA ROB reviews are separate from, and in addition to the responsible Institutional Animal Care and Use Committee (IACUC) review(s). Further information may be required if the proposal is successful.

CBD SBIR Projects Requiring Human Subjects, Human Anatomical Substances, and/or Human Data

Refer to the DoD Program BAA for Research Involving Human Subjects and Recombinant DNA Molecules.

Companies should plan carefully for any research involving human subjects, human data, and/or human biospecimens (e.g., blood, saliva, tissue), to include cadaveric specimens, hereafter referred to as “research”, in addition to the use of any chemical or biological warfare agents, and use of any agents associated with “Dual Use Research of Concern (DURC)”. The mandatory DoD level review of this research is typically no greater than four (4) months.

Projects under CBD SBIR awards involving the use of human subjects shall not be proposed for any Phase I Period of Performance but may be proposed during the Phase II proposal submission.

Written authorization to begin the research under the applicable protocol(s) proposed as part of the CBD SBIR/STTR program will be issued after the contract award in the form of an approval memo from the U.S. Army Medical Research and Development Command (MRDC), Office of Human Research Oversight (OHRO), and the Research Oversight Board (ROB) of the Defense Threat Reduction Agency (DTRA), both of which provide DoD compliance oversight to the CBD SBIR and STTR program office.

The offeror is expressly forbidden from beginning the research in any manner prior to these approvals. Furthermore, modifications to approved protocols require review and approval by the OHRO prior to implementation.

Non-compliance with these terms and conditions may result in withholding of funds and/or the termination of the award. The OHRO and DTRA ROB reviews are separate from, and in addition to the responsible Institutional Review Board (IRB) review(s). Further information may be required if the proposal is successful.

CBD – 10

CBD SBIR 25.4 Release 4 Topic Index

CBD254-001 Alternatives to Improve Medical Countermeasure (MCM) Logistics and Administration

CBD254-002 Production of Saline Solutions and Sterile Water Forward Deployed for Soldier Health Care

CBD254-003 Regenerable CO2 Scrubbing in a Self-Contained Breathing Apparatus

CBD254-004 Prophylactics/Therapeutics for Neurotoxin Exposure

CBD – 11

CBD254-001 Alternatives to Improve Medical Countermeasure (MCM) Logistics and Administration

OUSD (R&E) CRITICAL TECHNOLOGY AREA(S): Biotechnology

OBJECTIVE: Eliminate cold chain requirements for storage and transport of DoD relevant medical countermeasures (MCM).

DESCRIPTION: The Department of Defense has a need for technologies and approaches to eliminate the cold chain requirements for storage and transportation of medical countermeasures (MCM). This will enable more efficient and expeditionary administration of these critical products through a minimized logistics tail. Existing DoD Chemical and Biological Defense Program developed MCMs will be selected for assessment alongside (1) thermostabilizing technologies, (2) alternative formulations, and or (3) novel routes of administration for long-term MCM efficacy and stability in the absence of cold chain.

PHASE I: Performers will have demonstrated Advanced Development Feasibility through proof-of-concept studies showing technology application and use. Performers should also demonstrate how their technology integrates into DoD manufacturability and sustainment, as well as their regulatory experience and/or strategy. Lastly, performers will be asked to outline a commercialization strategy that involves long-term DoD access. Multiple awards anticipated.

PHASE II: Performers will have demonstrated Prototype Feasibility by demonstrating stabilization of DoD-manufactured MCM(s) through exposure to extended temperature variable trials (i.e., 25°C; - 40°C), for periods extending for at least six months and ideally a year or more.). In addition to stability, efficacy of thermostabilized MCMs will be evaluated using appropriate testing that may include in vitro assays, bridging assays demonstrating equivalency or animal models against current MCM formulations. Multiple awards anticipated.

PHASE II - Direct to Phase II: Eligible Phase II applicants may also apply directly to Phase II awards with support from third-party investors or strategic partners and USG matched funds.

PHASE III DUAL USE APPLICATIONS: Beyond DoD, effective and efficient cold chain management maximizes utilization of healthcare resources, reduces cold chain products wastage, and improves the quality of health services through increased stability of pharmaceutical supply chain and logistics.

REFERENCES:

1. Dole MJ, Kissane JM. Medical Logistics Lessons Observed During Operations Enduring Freedom and Iraqi Freedom. US Army Med Dep J. 2016 Apr-Sep;(2-16):119-23. PMID:

27215878.

2. Joint Publication 4-02, Joint Health Services (Washington, DC: U.S. Government Publishing Office [GPO], September 2018).

3. Army Health System Doctrine Smart Book (Washington, DC: U.S. Government Publishing Office [GPO], March 2023).

4. Matthew Marsh and Ryan Hampton, “Army Medicine’s Critical Role in Large-Scale Combat Operations: Enable the Force,” Military Review 102, no. 4 (July-August 2022), accessed 19 December 2024, https://www.armyupress.army.mil/Portals/7/PDF-UA-docs/Marsh-and- Hampton-UA.pdf.

KEYWORDS: Cold chain, medical countermeasure, MCM, formulation, stability, temperature-sensitive https://www.armyupress.army.mil/Portals/7/PDF-UA-docs/Marsh-and-Hampton-UA.pdf https://www.armyupress.army.mil/Portals/7/PDF-UA-docs/Marsh-and-Hampton-UA.pdf

CBD – 12

CBD254-002 Production of Saline Solutions and Sterile Water Forward Deployed for Soldier Health Care

OBJECTIVE: Provide a far-forward capability for producing sterile saline and water for injection solutions for soldier healthcare.

DESCRIPTION: The Department of Defense requires vast quantities of sterile saline and sterile water for injection for treatment of wounded soldiers. Sterile saline and water are both commonly used for wound cleansing, particularly for soldiers encountering mustard or blistering chemical warfare agents.

Sterile saline for intravenous use is the most commonly used crystalloid rehydration solution used in patient care. Sterile water for injection is also used for medication dilution to reconstitute powdered medications or dilute concentrated solutions, inhalation therapy to humidify air or deliver medications via nebulizers, and laboratory use to prepare samples and reagents.

• The current shortage in IV saline across the entire US was due to flooding in 1 factory in

North Carolina affected by Hurricane Helene. This shortage affected every health care facility in the country; if such a shortage occurred during large scale military operations, it would have an adverse effect on military health care.

• Sterile saline and water weigh 1 KG (2.2 lbs) for each 1 liter bag; shipping all of these bags to remote locations consumes large quantities of resources that could be repurposed to other warfighting uses if these solutions could be prepared forward deployed rather than in CONUS. Providing alternate locations for production mitigates DOD’s risk for supply chain management and decreases resources required for shipment of critical pharmaceutical products.

• Successful applicants will be chosen based on the soundness of the proposal, demonstrated pharmaceutical production experience, and deep knowledge of pharmaceutical manufacturing.

PHASE I: Demonstrate proof of concept production of drug substance sterile saline and sterile water produced using nonsterile source water made under Current Good Manufacturing Practice (CGMP) regulations using equipment that can be packaged in no more than 2 CONEX containers (20 ft wide, 40 ft long). Devise and implement a Quality By Design approach for production consistent with FDA guidelines implementing robust metrology, in-line process analytical testing, automation and informatics. Certificates of Analysis (COAs) should be provided for proof of concept runs to demonstrate successful compliance with applicable USP and FDA standards. Successful Phase 1 performers will show product production and a clear plan to achieve success for engineering runs required in Phase II.

PHASE II: Finalize equipment package and processes (critical process parameters, process automation, real-time monitoring, informatics, quality systems) necessary for fill finish production of sterile saline and water for injection packaged in IV bags. Sterile saline and water for injection packaged in IV bags must meet USP criteria for production. Demonstrate production of sterile saline and water for injection in IV bags in engineering runs to support an Abbreviated New Drug Application for the Food and Drug Administration. A successful Phase II performer will show actual production of sterile IV saline and water for injection under CGMP with acquired data to support a Drug Master File (DMF) and an Abbreviated New Drug Application (ANDA) submission.

PHASE II - Direct to Phase II: Eligible Phase II applicants may also apply directly to Phase II awards with support from third-party investors or strategic partners and USG matched funds. This program is

CBD – 13

well positioned as an inject to the MCM MFRO (Medical Countermeasures Manufacturing Optimization) program in JPEO for follow-on funding and work. Phase II performers will be chosen based on results achieved in Phase II. The expected outcome is an ANDA submission to the FDA for production of sterile IV saline and water for injection.

PHASE III DUAL USE APPLICATIONS: Development of a field-portable method of making IV saline solutions and water for injection would be a very useful tool in the aftermath of a national emergency or in the aftermath of a national shortage due to damage to US based manufacturing. The recent damage to the Baxter Healthcare plant in North Carolina after Hurricane Helene shows how vulnerable the US is to supply chain risks associated with these essential pharmaceutical products.

The needs of the US military are focused on producing needed sterile solutions far forward to minimize shipment of water solutions from the US and to provide redundancy in case of factory failures in the US. A Phase III performer will demonstrate at scale production of sterile IV saline and water for injection that meets FDA standards of CGMP production.

REFERENCES:

1. M. Mazer-Amirshahi and E. Fox, Saline Shortages – Many Causes, No Simple Solution. New England Journal of Medicine, 378, 16 p.1472 2018.

2. https://www.fda.gov/drugs/updates-2024-hurricane-season/hurricane-helene-baxters-manufacturing-recovery-north-carolina

KEYWORDS: sterile solutions, intravenous solutions, water for injection, water for irrigation, ANDA, CGMP, COA, Quality By Design, pharmaceutical production https://www.fda.gov/drugs/updates-2024-hurricane-season/hurricane-helene-baxters-

CBD – 14

CBD254-003 Regenerable CO2 Scrubbing in a Self-Contained Breathing Apparatus

OBJECTIVE: To develop a continuously regenerable CO2 scrubbing system to extend the operating lifetime of a self-contained breathing apparatus (SCBA) while maintaining size and weight limits needed for reduced logistical burden.

DESCRIPTION: A SCBA is a type of respiratory protection device that provides breathing gas from a source independent of the surrounding atmosphere. A closed-circuit SCBA or “rebreather” re-circulates the breathing air after the carbon dioxide has been removed and the oxygen content restored.

Carbon dioxide is typically removed using an absorbent material such as soda lime that cannot be regenerated and must be replaced when expended. Additionally, this carbon dioxide removal process uses an exothermic reaction where the generated heat must be removed using ice or re-freezable cooler packs,1 thus increasing the weight and logistics.

A novel approach is needed to overcome the weight and heat generation associated with carbon dioxide removal. Recently, an explosion of research on carbon capture technology has led to the discovery of new sorbent materials to remove low levels of CO2 while operating in humid environments.2,3 As the scale of environmental carbon capture is so large, the only cost-effective sorbents must be easily regenerable. To extend the lifetime of a SCBA CO2 scrubber, the use of these types of sorbents would require a system capable of sorbent regeneration while in operation. One potential solution for this would be a miniature vacuum-swing adsorption system. Any system will still be required to meet size, weight, and heat generation requirements. Technologies that are non-hazardous in use and disposal are desirable.

Ultimately, the goal is to develop a longer lasting, lower profile, and lighter weight SCBA for unique military operations. Such operations may include prolonged entry into immediately dangerous to life and health (IDLH) atmospheres or unknown CBRN environments.

PHASE I: Develop a regenerable, high humidity, low-pressure carbon dioxide removal system that offers significant improvements in the weight and heat generation associated with currently used absorbent materials and ice packs. Determine potential sorbents for relevant SCBA environments.

Demonstrate feasibility of proposed enabling technology through computer models based on existing data. Identify key performance parameters and test criteria relevant to closed-circuit SCBA applications. Establish test set up and procedures to assess and validate proposed approach. Fabricate physical “breadboard” model and conduct bench top testing to characterize the performance of the proposed solution. Record data related, but not limited to, the following: adsorption capacity, desorption rate, adsorption enthalpy (thermodynamic properties), power requirements, and efficiency under relevant temperature/humidity conditions.

PHASE II: Refine and optimize Phase I breadboard model to improve carbon dioxide removal capacity and performance. Perform follow-on bench top evaluations to verify improvements made to the basic enabling technology. Modify test setup and improve test procedures as required. Develop functional scalable prototype by incorporating enabling technology into a suitable test bed (e.g., carbon dioxide storage platform or container). Characterize test bed performance under an operational relevant range of external environmental (temperature/humidity) conditions and in-mask heat/humidity loads. The evaluations should include characterizing the breathing air quality, release of any by-products, exothermic reactions, and other factors relevant to the technology. Based on results obtained, implement necessary refinements to the scalable test bed model.

PHASE III: Fully integrate solution into a full-scale, fully-functional prototype containment unit comparable to the size and weight of a typical re-breather carbon dioxide absorbent and cooling

CBD – 15

mechanism. Demonstrate ability of the technology to be incorporated into a fully-functional closed-circuit SCBA through modification of an existing off-the-shelf system. Expand applications to other commercial markets to include industrial and homeland defense closed-circuit SCBAs.

PHASE III DUAL USE APPLICATIONS: Potential alternative applications include firefighting, industrial, mine rescue, and escape SCBAs. Other possible applications include gas purification, gas separation, and underwater breathing devices (scuba).

REFERENCES:

1. “BioPak 240R Revolution.” 2011. Biomarine, Inc. <Home | Biomarine, Inc.>

2. “NETL Explores Sorbent-Based Direct Air Capture Systems for the Removal of

Atmospheric CO2.” 2022. <NETL Explores Sorbent-Based Direct Air Capture Systems for the Removal of Atmospheric CO2 | netl.doe.gov>

3. Wang Q., Chen, Y. Liu, P., Wang, Y., Yang, J., Li, J., Li, L. “CO2 Capture from High-Humidity Flue Gas Using a Stable Metal–Organic Framework.” Molecules 2022, 27, 5608. <CO2 Capture from High-Humidity Flue Gas Using a Stable Metal&ndash;Organic Framework>

KEYWORDS: carbon dioxide scrubbing, physisorption, regeneration, self-contained breathing apparatus https://www.biomarineinc.com/ https://netl.doe.gov/node/11941 https://netl.doe.gov/node/11941 https://netl.doe.gov/node/11941 https://www.mdpi.com/1420-3049/27/17/5608 https://www.mdpi.com/1420-3049/27/17/5608 https://www.mdpi.com/1420-3049/27/17/5608

CBD – 16

CBD254-004 Prophylactics/Therapeutics for Neurotoxin Exposure

OBJECTIVE: A biological agent is sought to prevent illness upon exposure to chemical warfare nerve agents, to include G-type or V- type neurotoxins, by either administering a prophylactic before anticipated exposure or administering a therapeutic after symptoms of exposure. Phase II will demonstrate robust deactivation of neurotoxins in vitro with foundational studies targeting appropriate efficacy and pharmacokinetics to include physiological half-life, clearance, and tolerance.

DESCRIPTION: The primary problem this topic addresses are gaps in our ability to sustain troops on the battlefield under exposure to chemical weapons. Furthermore, chemical attacks on the homeland would place U.S. civilians in harm’s way without an effective remedy. Organophosphorus compounds pose significant threats to military personnel. At lethal doses these agents act irreversibly on the nervous system, resulting in uncontrolled convulsions followed by rapid death. Butyrlcholinesterase is human enzyme that stoichometrically binds these compounds and prevents them from reaching their physiological targets. However, when produced endogenously, these large enzymes are difficult to prophylactically deliver in sufficient doses to mitigate expected organophosphorus compound exposure. Human Paraoxonase has been demonstrated to detoxify organophosphorus compounds.

Phosphotriesterases (PTEs) and Organophosphate Acid Anhydrolase (OPAA) are enzymes that neutralize G-type nerve agents both environmentally and in the human body. Mutant PTE has even been developed for detoxification of the highly toxic V-type agents. Biodistribution profiles and protease susceptibility characteristics have prevented these enzyme-classes from employment as prophylactic agents or as post- exposure therapeutics.

This topic solicits innovative chemistries and approaches to render such enzymes stable in circulating blood over for up to several months and at sufficient levels to mitigate exposure to operationally relevant quantities of organophosphorus compounds while also considering biodistribution, toxicity, and clearance. Prophylactic and therapeutic doses of protected OPAA and PTE would ideally be injected intramuscularly or subcutaneously to rapidly neutralize nerve agents in vivo and minimize acute and chronic injuries. A prophylactic and therapeutic chemical medical countermeasure comprised of human- compatible formulations containing neuro-protective enzymes would enable military and ultimately civilian use for protection against nerve agents in combat scenarios and therapeutic treatment in combat and non-combat scenarios.

PHASE I: Phase I will demonstrate ability to perform assays probing PTE and/or OPAA turnover rates for chemical reactions on model compounds that mimic deactivation of a multiple nerve agents.

The studies will characterize catalyst performance under various destabilizing environments such as thermal and chemical denaturing conditions comparing wild-type enzyme and enzyme with some degree of stabilization chemistry employed. A target is demonstrating turnover rates for stabilized enzyme that approach wild-type values. Phase I will provide a plan for access to multiple classes of nerve agents and the ability to work with these samples which may involve exploiting or establishing an enabling collaboration with a partner having these abilities.

PHASE II: Phase II will deliver prototype MCMs wherein the enzyme has been demonstrated to retain catalytic activity after being stabilized against various denaturing conditions. The delivered compounds, produced in mg quantities, will be characterized for deactivation of multiple classes of nerve agents under chemical and biochemical conditions comparable to physiological exposure.

Turnover rates and lifetimes will be rigorously documented for each compound for multiple nerve agents. Top candidate drugs/biological agents emerging from these systematic studies will be bolstered

CBD – 17

to increase performance in both activity and stability. Ultimately at the end of Phase II, mg quantities of the best performing compounds will be delivered for Phase III animal studies.

PHASE III: The goal of Phase III work will be to evaluate the protective formulations for the peripheral and central nervous systems though animal studies. Evaluating how the compounds distribute throughout the body, accumulate in specific tissues, and are cleared will enables the refinement of further design to enhance stability, prolong circulation time, and catalysts compounds remain active for longer durations. Ultimately, Phase III will pursue (1) intramuscular administration with (2) peripheral and central nervous system entry and (3) long duration of circulation and enzyme activity. Higher animal models beyond mice and towards enabling human clinical trials is a goal of Phase III.

PHASE III DUAL USE APPLICATIONS: The delivered therapeutic will allow medical intervention for the domestic public that would be needed after a domestic involving G-type nerve agents or during an organophosphorus insecticide accidental spill or exposure. The treatment would also be available for CONUS troops.

REFERENCES:

1. Bigley, A.N.et al. Overcoming the Challenges of Enzyme Evolution to Adapt

Phosphotriesterase for V-Agent…

This is the start of the file's text. The full file is on GovTribe.

File details come from the government source that posted it. Updated .